I heard the statistician say, “The drug does not have sufficient activity to study further in this population.” It was my co-investigator on GOG study 229C, Gefitinib in the Treatment of Advanced and Recurrent Endometrial Cancer (see related extended abstract in this issue*), calling from Roswell Park in Buffalo. He had just completed the analysis of data from 26 women treated on our study – a study which had been five years in the making from concept to clinical trial.
Keywords: Clinical trials, gefitinib
How to Cite:
Leslie, K. K., (2013) “Gynecologic Oncology Group Study 229C: Personal Reflection”, Proceedings in Obstetrics and Gynecology 3(4), 1-2. doi: https://doi.org/10.17077/2154-4751.1223
Rights: Copyright © Kimberly K. Leslie, 2013.